1 active not recruiting. 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 1 | Active not recruiting 1 |
Follow Refractory Multiple Myeloma: new trials by email Literature Review of Refractory Multiple Myeloma trials Research Report on Refractory Multiple Myeloma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant Autologous Hematopoietic Stem Cell Transplantation, Laboratory Biomarker Analysis, Lenalidomide - DS Stage I Multiple Myeloma, DS Stage II Multiple Myeloma | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 460 | 2004-12-15 | 2026-08-26 |
Multiple Myeloma (1) · Smoldering Multiple Myeloma (1)
Blood Protein Disorders (1) · Cardiovascular Diseases (1) · Hematologic Diseases (1) · Hemic and Lymphatic Diseases (1) · Hemorrhagic Disorders (1) · Hemostatic Disorders (1) · Hypergammaglobulinemia (1) · Immune System Diseases (1) · Immunoproliferative Disorders (1) · Lymphoproliferative Disorders (1) · Neoplasms (1) · Neoplasms by Histologic Type (1) · Neoplasms, Plasma Cell (1) · Paraproteinemias (1) · Precancerous Conditions (1)
Lenalidomide (1) · Melphalan (1) · Peripheral Blood Stem Cell Transplantation (1) · Stem Cell Transplantation (1)
National Cancer Institute (NCI) (1)
United States (1)
U10CA031946 (1), U10CA180821 (1)